Document is current
Any future updates will be listed below
-
Authors
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Jen, Wei-Ying https://orcid.org/0000-0002-9339-3362
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Daver, Naval G. https://orcid.org/0000-0001-7103-373X
Xiao, Lianchun
Reville, Patrick K. https://orcid.org/0000-0001-8433-3360
Issa, Ghayas C. https://orcid.org/0000-0002-4339-8683
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Wang, Sa A. https://orcid.org/0000-0001-9385-9911
Mullin, Jillian K.
Pierce, Sherry
Bradley, Corey
Borthakur, Gautam https://orcid.org/0000-0001-7679-6453
Maiti, Abhishek
Alvarado, Yesid https://orcid.org/0000-0002-1652-7937
Pemmaraju, Naveen https://orcid.org/0000-0002-1670-6513
Ferrajoli, Alessandra
Swaminathan, Mahesh https://orcid.org/0000-0001-5959-397X
Ohanian, Maro
Abbas, Hussein A. https://orcid.org/0000-0003-2946-3562
Hammond, Danielle https://orcid.org/0000-0002-6017-2264
Burger, Jan https://orcid.org/0000-0002-6177-7572
Haddad, Fadi
Montalban-Bravo, Guillermo https://orcid.org/0000-0002-4533-5176
Chien, Kelly https://orcid.org/0000-0001-6024-1613
Masarova, Lucia
Yilmaz, Musa https://orcid.org/0000-0002-4498-4895
Jain, Nitin
Andreeff, Michael
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Kornblau, Steven https://orcid.org/0000-0002-5990-9548
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Konopleva, Marina Y. https://orcid.org/0000-0002-9347-2212
Kantarjian, Hagop M. https://orcid.org/0000-0002-1908-3307
-
Funding
Funding for this research was provided by:
UT | University of Texas MD Anderson Cancer Center (CA100632)
AbbVie Inc. | AbbVie Biotherapeutics
Leukemia and Lymphoma Society (AWD00006066)
V Foundation for Cancer Research (D2018 - 013)
- License Information
-
More Information
Article History
Received: 25 November 2024
Revised: 10 January 2025
Accepted: 4 February 2025
First Online: 25 February 2025
Competing interests
: CDD reports research Support from: Abbvie, Astex, BeiGene, BMS, Cleave, Foghorn, Jazz, Loxo, Servier and Personal fees from: Abbvie, Astellas, BMS, GSK, GenMab, Genentech, Gilead, Jazz, Loxo, Notable Labs, Servier, Schrodinger. NGD has received grants or contracts from Hanmi, Trovagene, Fate Therapeutics, Novimmune, and GlycoMimetics; consulting fees from Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, and Agios; and grants or contracts and consulting fees from Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead Sciences, Inc., Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, and Trillium. GCI received consultancy or advisory role fees from Novartis, Kura Oncology, Syndax Pharmaceuticals, Abbvie and NuProbe and received research funding from Celgene, Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology, Astex and NuProbe. NJS has received consulting fees from Pfizer, GlaxoSmithKline, NKARTA, Autolus, and Sanofi; research funding from Takeda Oncology, Astellas Pharma, Xencor, Stemline Therapeutics, and NextCure; and honoraria from Adaptive Biotechnologies, Novartis, Amgen, Takeda Oncology, Pfizer, Astellas Pharma, Sanofi, and BeiGene. HA has received consulting fees from Molecular Partners; research funding from Genentech, GlaxoSmithKline, and EBD-300; and honoraria from Illumina. FR has served as a consultant for AbbVie, reports receiving research grants from Astellas Pharma Inc. and Celgene/BMS, and has received honoraria from Astellas Pharma Inc. and Celgene/BMS. EJ has received consulting fees and research funding from AbbVie, Adaptive Biotechnologies, Amgen, Ascentage, ASTX Pharmaceuticals, AstraZeneca, Autolus, BMS, Genenenctech, Hikma, Kite, Novartis, Pfizer, Takeda Oncology, and Jazz. MYK has received consulting fees from AbbVie, AstraZeneca, Auxenion, Bakx, Boehringer, Dark Blue Therapeutics, F Hoffman-La Roche, Genentech, Gilead, Janssen, Legend, MEI Pharma, Redona, Sanofi, Sellas, Stemline, and Vincerx; research funding from AbbVie, Allogene, AstraZeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, Precision, Rafael, Sanofi, and Stemline; honoraria from AbbVie, Baxk Therapeutics, Genentech, and Stemline Therapeutics; stock options in Reata Pharmaceuticals; and holds patents with Novartis, Eli Lilly, and Reata Pharmaceutical. HMK has received honoraria, consulting or advisory role fees from AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda and research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis. TMK has received research funding from AbbVie, Amgen, Astex, BMS, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, GenFleet Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion Therapeutics, GlycoMimetics, Sellas, and Regeneron Pharmaceuticals; and has received personal fees from AbbVie, Agios, BMS, Genentech, Hikma, Jazz Pharmaceuticals, Novartis, Servier, Sellas, and PinotBio.
: The University of Texas MD Anderson Cancer Center Institutional Review Board (2016–0979).
